Main Research Findings

1) Administration of Argireline was found to increase the amount of Type I collagen and improve the overall histological structure of the skin and provide overall rejuvenating effects.
2) Research shows that various analogues of the peptide Argireline effectively reduce wrinkle formation and enhance skin permeation.

Selected Data
2) This study conducted by researchers Wang et al investigated the effects of Argireline on skin aging in a subacute aged mouse model induced by D-galactose. A total of forty-two-month-old Kunming mice, with an average weight of 20 ± 2 g, were randomly assigned to four groups, each containing ten mice: a normal control group, an aged model group, a placebo control group, and an Argireline-treated group. All mice were housed individually according to their respective groups, maintained under the same environmental conditions, and provided with a standard diet and sufficient water [1].
The normal control group received daily subcutaneous injections of saline at a dose of 0.1 ml/10 g in the nape and back skin. The other three groups were injected subcutaneously with 0.1 ml/10 g of 10% D-galactose daily in the same regions for six weeks to establish subacute aging models. D-galactose-induced aging is a widely accepted laboratory method to simulate natural aging due to its impact on multiple cellular and molecular pathways. Aging induced by D-galactose is associated with oxidative stress, mitochondrial dysfunction, calcium homeostasis imbalance, non-enzymatic glycosylation, telomere shortening, telomerase inactivation, and a decline in immune function. Studies indicate that D-galactose-treated mice can achieve senescence comparable to 21-month-old naturally aged mice.
For the placebo and Argireline-treated groups, hair was shaved on the backs of the mice to create a 2 × 2 cm area for topical application. The Argireline-treated group received a 10% Argireline solution in an oil-and-water emulsion, applied twice daily, whereas the placebo group received the non-active emulsion without Argireline. This regimen was maintained throughout the six-week D-galactose treatment period [1].
At the end of the experiment, skin tissues approximately 1 × 1 cm in size were excised from the treated sites of the placebo and Argireline-treated groups. Corresponding tissues were also collected from the normal control and aged model groups. The skin samples were processed into paraffin sections and stained using hematoxylin–eosin (HE) and picrosirius–polarization (PSP) methods. HE staining was employed to observe histopathological changes in the skin tissue, such as epidermal and dermal structure alterations, while PSP staining was used to differentiate type I and type III collagen fibers [1].
PSP staining is a selective histochemical method for collagen detection that allows visualization of collagen fibers under polarized light. Type I collagen fibers, which are mature and thick, appear yellow or red due to their strong refractive index. In contrast, type III collagen fibers, which are young and thin, display green coloration because of their weaker refractive index. This technique enables a clear distinction between the collagen types and allows for semi-quantitative comparison of the amounts of type I and type III collagen fibers across different experimental groups. Image-ProPlus software was used to analyze the stained sections and quantify the collagen content.
The study employed statistical analysis using the SPSS software to assess differences among the experimental groups. The primary objectives were to evaluate histopathological alterations in the skin, determine the relative content of type I and type III collagen fibers, and assess the potential protective effects of Argireline against D-galactose-induced skin aging. By comparing the Argireline-treated group with the placebo control, aged model, and normal control groups, the researchers aimed to establish whether Argireline could mitigate age-related structural changes in the skin, preserve collagen integrity, and potentially slow the progression of skin senescence [1].
Overall, this study combined a well-established subacute aging mouse model with targeted histological techniques to investigate the therapeutic potential of Argireline for age-related skin degeneration. The methods included systematic subcutaneous and topical treatments, detailed tissue collection, and advanced collagen visualization under polarized light, providing a comprehensive framework to evaluate the anti-aging effects of the compound at both morphological and molecular levels [1].
1) The research team of Lim et al investigated the synthesis, characterization, skin permeation, and functional effects of Arg0 and its peptide analogues, as well as their potential neuroprotective effects using human dental pulp stem cells (DPSC) differentiated into neurons. The peptides were synthesized using conventional solid-phase peptide synthesis techniques based on FMOC chemistry on Rink-amide resin, with modifications specific to each analogue. Purification was achieved through preparative high-performance liquid chromatography and other standard purification methods. Physicochemical and toxicity properties of the peptides were predicted in silico to provide insight into their potential stability, solubility, and safety [2].
To prepare for in vitro studies, saturated peptide solutions were formulated in water or propylene glycol (PG). Excess peptide was added to each solvent in Eppendorf tubes, shaken at room temperature for 48 hours, and centrifuged to remove undissolved material. The resulting supernatant was collected in amber ampoules for subsequent assays. The solubility of each peptide determined the concentration used in donor solutions for skin permeation experiments, with compounds exceeding 1% w/w maintained at this level to balance efficacy and cost considerations.
Human dermatomed skin was obtained from cadaveric donors; the skin was visually inspected to ensure no structural compromise, with any tissue showing abnormally high peptide permeation at early time points discarded. Vertical Franz diffusion cells with an effective area of 1 cm² were used to evaluate in vitro skin permeation. The epidermis-facing donor compartment received 400 μL of saturated peptide solution, while the receptor compartment contained 4.8 mL of 1X PBS, maintained at 32 °C to simulate physiological skin surface temperature. Magnetic stirring at 180 rpm ensured uniform distribution in the receptor compartment. Samples were withdrawn at predetermined intervals, replaced with fresh buffer, and analyzed for peptide content using HPLC. Mobile phase compositions were optimized individually for each peptide. All permeation experiments were performed in triplicate to ensure reproducibility [2].
For cellular studies, primary human DPSC were obtained from a single donor and cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were maintained at 37 °C with 5% CO₂ and used between passages 4 and 9. To induce neuronal differentiation, DPSC were seeded in 24-well plates and allowed to adhere for 24 hours. The growth media was then replaced with neural induction media consisting of Neurobasal-A medium supplemented with B-27, penicillin/streptomycin, epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF). Media was replaced every three days, and differentiation was maintained for 12–14 weeks to generate DPSC-derived neurons [2].
The functional efficacy of the peptides was assessed through their ability to inhibit glutamate release in DPSC neurons. Arg0 and its analogues were prepared in PBS and added to the neuronal cultures at defined concentrations: 2 mM for Arg0 and Arg1, and near-saturated concentrations of 1.35 mM and 1.27 mM for Arg2 and Arg3 due to limited solubility. After 5 hours of peptide exposure, the cultures were washed and treated with depolarizing media containing HEPES, calcium chloride, potassium chloride, and sodium chloride to stimulate glutamate exocytosis. Following a 23-hour depolarization period, the media was collected, and glutamate levels were measured using a commercial fluorometric assay kit. The assay relied on a coupled enzyme system where glutamate reacts with NADP⁺ to produce NADPH, which is detected by a fluorescence sensor. Fluorescence was read at excitation/emission wavelengths of 540/590 nm, allowing quantitative assessment of peptide-mediated inhibition of glutamate release [2].
Collectively, this study established a framework for evaluating Arg0 and its analogues, encompassing chemical synthesis, purification, physicochemical characterization, skin permeation, and neuroprotective function in human-derived neuronal cultures. The combination of in vitro skin models and differentiated DPSC neurons provided a robust platform to assess both topical delivery and neuronal activity modulation. The experimental approach integrated advanced analytical techniques, including HPLC for permeation quantification and fluorometric glutamate assays for functional evaluation, ensuring rigorous and reproducible data. Through these methods, the study aimed to characterize the therapeutic potential of Arg0 peptides, particularly their ability to penetrate human skin and influence neuronal signaling, thereby supporting further development of these compounds for applications in dermatology and neuroprotection [2].

Discussion
2) The study performed by Wang et al evaluated the effects of Argireline on skin aging in a subacute aged mouse model induced by D-galactose, focusing on histological changes in the skin and collagen composition. After six weeks of treatment, all mice survived and showed no observable side effects, indicating that the experimental procedures, including subcutaneous injections and topical applications, were well-tolerated. Histological assessment of the skin was performed using hematoxylin–eosin (HE) staining and picrosirius–polarization (PSP) staining, which enabled evaluation of dermal structure and collagen fiber composition, respectively [1].
HE staining revealed marked differences between the experimental groups. In the aged model group, the dermal layer of the skin was significantly thinner than that of the normal control group. Collagen fibers in the dermis were reduced in quantity and appeared loosely bound, indicating structural deterioration consistent with aging. In contrast, the Argireline-treated group displayed substantial improvements in skin morphology. The dermis was thicker, collagen fibers were more abundant, and the fibers were dense and tightly packed, demonstrating a restoration of structural integrity compared to the aged model group. The placebo control group, which received the carrier emulsion without Argireline, did not exhibit meaningful differences from the aged model group, confirming that the observed effects in the Argireline group were specifically attributable to the active compound rather than the vehicle or topical application procedure [1].
Further analysis using PSP staining provided insights into the composition and organization of collagen fibers, particularly type I and type III collagen. In the aged model group, collagen fibers were thinner, shorter, and irregularly organized compared with the normal control group. The content of type I collagen, which represents mature and mechanically robust fibers, was decreased, whereas the content of type III collagen, indicative of immature or newly synthesized fibers, was increased. These changes reflect typical features of skin aging, including reduced tensile strength and structural disorganization. In the Argireline-treated group, the collagen fibers were closely aligned and regularly arranged. Notably, type I collagen fibers were increased while type III collagen fibers were decreased, suggesting a reversal of age-related collagen remodeling and an enhancement of skin structural stability. The placebo control group again showed negligible differences compared with the aged model group, reinforcing that Argireline itself mediated these effects.
Quantitative image analysis and statistical evaluation corroborated the histological observations. Compared with the normal control group, the aged model group exhibited a statistically significant decrease in type I collagen fibers and an increase in type III collagen fibers. These changes confirmed the successful establishment of the subacute aging model. No significant differences were observed between the placebo control and aged model groups, demonstrating that the vehicle alone did not influence collagen content or organization. In the Argireline-treated group, type I collagen fibers significantly increased, and type III collagen fibers significantly decreased compared with the aged model group. These findings indicate that Argireline effectively counteracted age-related changes in dermal collagen composition, restoring a balance favoring more mature, mechanically stable fibers [1].
Overall, the results demonstrate that Argireline treatment significantly ameliorates age-associated deterioration of skin structure and collagen composition in the D-galactose-induced subacute aging mouse model. The compound promoted an increase in type I collagen and a decrease in type III collagen, contributing to denser, more organized dermal tissue and effectively resisting the progression of skin aging. In contrast, placebo treatment had no significant impact on dermal thickness or collagen composition, confirming that the observed anti-aging effects were specifically attributable to Argireline. These findings collectively provide strong evidence that Argireline possesses potent anti-wrinkle and skin-protective properties, offering a promising strategy for mitigating the histological and structural changes associated with cutaneous aging [1].
1) This study completed by Lim et al focused on the design, structural modification, physicochemical characterization, skin permeation, and functional activity of four peptide analogues, Arg0, Arg1, Arg2, and Arg3, with potential anti-wrinkle effects. Arg0 served as the parent compound, and the three analogues, Arg1, Arg2, and Arg3, that were chemically modified to enhance lipophilicity and reduce the formation of zwitterions, which could affect solubility and skin permeation. Structural modifications were primarily applied to the amino acid side chains. In all three analogues, the carboxylic acid functional groups at positions A and B were esterified, thereby reducing their ability to ionize. Arg2 and Arg3 underwent additional modifications to the guanidine functional group: in Arg2, the guanidine was converted to an acetamide at both terminal nitrogen atoms, whereas in Arg3, it was transformed into a bis-carbamate functional group ending with tertiary butyl groups. These structural modifications were designed to reduce ionization and increase hydrophobicity, enhancing the potential for transdermal delivery [2].
Physicochemical characterization revealed that these modifications significantly altered the properties of the peptides. Specifically, esterification and additional modifications caused a substantial decrease in the pKa of ionizable atoms, indicating a lower tendency for these groups to protonate and form charged ions. For example, in Arg2 and Arg3, the pKa of certain guanidine atoms dropped from approximately 13 to 0.5, rendering them largely non-ionizable under physiological conditions. Lipophilicity, measured as LogP, increased progressively from Arg0 to Arg3, with Arg3 achieving the most favorable LogP of 1.75. Molecular weights also increased due to the additional chemical groups, while Arg1 and Arg2 showed intermediate values of 917.05 Da and 1085.19 Da, respectively. These changes indicated that the analogues were more lipophilic and potentially more suitable for skin permeation, although all four compounds remained relatively large molecules due to their peptide nature.
The transdermal permeation of these peptides was evaluated using in vitro Franz diffusion cells, with propylene glycol (PG) serving as a solvent due to its known co-solvent and permeation-enhancing properties. In pure PG, Arg2 and Arg3 demonstrated significantly higher cumulative permeation through human skin compared to Arg0, with Arg2 achieving ~4.5-fold and Arg3 ~3.1-fold increases after 24 hours. Arg1, by contrast, showed slightly lower permeation than Arg0, though this difference was not statistically significant. Overall, PG enhanced the skin permeation of all peptides compared to water, although the effect varied among different analogues [2].
Further experiments tested the effect of varying PG concentrations in water including 30%, 50%, and 70%, on peptide permeation. At 30% PG, both Arg2 and Arg3 demonstrated significantly higher cumulative permeation than Arg0, with increases of ~2.5-fold and ~2.2-fold, respectively, whereas Arg1 showed markedly lower permeation. At 50% PG, Arg2 achieved an ~11.2-fold increase, and Arg3 a ~2.9-fold increase compared to Arg0. Interestingly, at 70% PG, the parent peptide Arg0 exhibited the highest permeation, while Arg1 remained consistently the least permeable across all solvent concentrations. In general, Arg2 and Arg3 were consistently superior to Arg0 and Arg1 in permeating skin, with the optimal PG concentration varying depending on the specific peptide [2].

Figure 1: Changes in cumulative permeation of the 4 different peptide analogues over 24 hours in response to varying concentrations of PG. A) 100% PG, B) 70% PG, C) 50% PG, D) 30% PG, E) 0% PG>
Functional activity of the peptides was assessed using primary human dental pulp stem cells differentiated into neurons. These cells were chosen due to their ability to differentiate into functional neurons while minimizing epigenetic variability compared to induced pluripotent stem cells. The assay measured glutamate release as a surrogate for acetylcholine release, providing an indirect evaluation of the peptides’ ability to inhibit neuronal exocytosis, which correlates with anti-wrinkle activity. Differentiation was confirmed as DPSC neurons exhibited significantly higher glutamate release than undifferentiated DPSC or blank controls [2].
Upon treatment with the peptides, inhibition of glutamate release varied substantially among analogues. Arg0 and Arg1 showed similar modest effects, reducing glutamate release by approximately 13–14% relative to control. Arg2, despite its superior skin permeation, demonstrated only ~4% inhibition, suggesting limited functional activity in this context. In contrast, Arg3 exhibited the most pronounced effect, reducing glutamate release by ~43%, indicating strong potential for anti-wrinkle activity. Overall, the peptides’ functional efficacy in descending order was Arg3, Arg1, Arg0, and Arg2.
In summary, structural modifications to the amino acid side chains of the peptide analogues successfully increased lipophilicity and altered ionization properties, enhancing skin permeation for Arg2 and Arg3. However, only Arg3 combined favorable physicochemical properties with high functional efficacy in inhibiting neuronal exocytosis, making it the most promising candidate for topical anti-wrinkle applications. These results highlight the importance of balancing skin permeation and biological activity in peptide-based therapeutics [2].

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9

[2] Lim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 2018;8(1):1596. Published 2018 Jan 25. doi:10.1038/s41598-017-18454-z

PEPTIDES PREFER THE COLD
Keep peptide vials refrigerated at all times to reduce peptide bond breakdown. DO NOT FREEZE. Most peptides, especially shorter ones, can be preserved for weeks if careful.
Always swab the top of the vial with an alcohol wipe, rubbing alcohol or 95% ethanol before use.
Before drawing solution from any dissolved peptide vial, fill the pin with air to the same measurement you will be filling with solution, ie. if you plan to take 0.1 ml, first fill the pin with 0.1ml of air, push the air into the vial, and then draw the peptide back up to the 0.1 ml marker. Doing so will maintain even pressure in the vial. Always remember to remove air bubbles from the pin by flicking it gently, pin side up, and pushing bubbles out. In addition, push out a tiny amount of solution to ensure there is no air left in the metal tip.

ONLY MIX WITH STERILE BACTERIOSTATIC WATER
The purity and sterility of bacteriostatic water are essential to prevent contamination and to preserve the shelf-life of dissolved peptides.
Push the pin through the rubber stopper at a slight angle, so that you inject the bacteriostatic water toward the inside wall of the vial, not directly onto the powder.
Lyophilized peptide should be stored at -20°C (freezer), and the reconstituted peptide solution at 4°C (refrigerated). Do not freeze once reconstituted.
NEVER SHAKE A VIAL TO MIX.

Air bubbles are unfavorable to the stability of proteins.

Argireline is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.